Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 0512 • ACR Convergence 2025
Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome
Karina Palomo-Arnaud¹, Janett C. Riega-Torres², Jose Martinez-Delgado³, Fernando Morales-Wong³, Jesus Mohamed-Hamsho³, Valeria Mata-Riega¹, Irma Cantu-Zapata¹, Luis Medina-Gomez¹, Miguel Betancourt-De la Torre¹, Aritze Chong-Amezcua¹, Dionicio A. Galarza-Delgado⁴ and Karim Mohamed-Noriega³, ¹Hospital Universitario "Dr. José Eleuterio González", Rheumatology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Ofthalmology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film. This is commonly observed…
Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Jason Sillitoe¹, Ewa Fiorentino-Rozek², Gerber Gomez³, Christian Fischer³ and Caroline Wilson¹, ¹North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ²Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, ³Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
Abstract Number: 2291 • ACR Convergence 2025
Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren’s Disease
Alejandro Gómez Gómez¹, Eric Kirkegaard-Biosca², Sergio H. Martínez Mateu³, Iago Alvarez Saez⁴, Natalia Boix- Martí⁵, Antonio Julià¹, Jose Luis Andreu⁶ and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³IMIDomics, Barcelona, Spain, ⁴Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁵Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disorder marked by mucosal dryness and ocular surface damage. For diagnosis, the ACR-EULAR 2016 criteria require the…
Abstract Number: 1680 • ACR Convergence 2025
Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Alen Zabotti¹, Valeria Manfrè¹, Maria Teresa Rizzo¹, Alessia Nano¹, Garifallia Sakellariou² and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy
Background/Purpose: Sjögren's disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features…
Abstract Number: 1392 • ACR Convergence 2025
Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
Margaret Essien and Ram Singh, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Sjögren's disease (SjD), an autoimmune condition with chronic inflammation in exocrine glands, is associated with increased risks of cancers. The impact of cancer on…
Abstract Number: 1223 • ACR Convergence 2025
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Alexis Ogdie¹, Astrid Rasmussen², Dana Orange³, Michelle Petri⁴, Caroline Shiboski⁵, Rebecca Haberman⁶, Mala Masson⁷, Daniel Goldman⁴, Peter Izmirly⁸, Brooke Cohen⁹, Jennifer Seifert¹⁰, Jennifer Anolik¹¹, Wade DeJager¹², Alan Baer¹³, Jill Buyon¹⁴ and Yvonne Lee¹⁵, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³The Rockefeller University, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸New York University Grossman School of Medicine, New York, NY, ⁹Yale Physician Associate Program, New Haven, CT, ¹⁰University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ¹¹University of Rochester Medical Center, Rochester, NY, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵Northwestern University, Chicago, IL
Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2290 • ACR Convergence 2025
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Alejandro Gómez Gómez¹, Sergio H. Martínez Mateu², Jose Luis Tandaipan³, Monica Fernandez Castro⁴, Guillermo gonzalez⁵, Sheila Melchor-Díaz⁶, Miren Uriarte Ecenarro⁷, Raúl Menor Almagro⁸, Paloma Vela Casasempere⁹, Beatriz Paredes-Romero¹⁰, Judit Font-Urgelles¹¹, Paula Estrada-Alarcón¹², Sara Manrique-Arija¹³, Mª Angeles Blazquez Cañamero¹⁴, Clara Moriano¹⁵, Juan José Alegre-Sancho¹⁶, Marina Rodríguez López¹⁷, Marta López¹⁸, Gema Bonilla¹⁹, Rafaela Ortega-Castro²⁰, Sara Maria Rojas Herrera²¹, Ignacio Braña²², Lilian López-Núñez²³, Javier Narváez²⁴, Jose Rosas Gómez de Salazar²⁵, Ruben D. López-Sánchez²⁶, Carles Galisteo Veiga²⁷, Javier Martínez-Ferrin²⁸, Jose Javier Pérez Venegas²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Lara Sánchez Bilbao³², José Andrés Román Ivorra³³, Rafael Cáliz-Cáliz³⁴, Belén Serrano-Benavente³⁵, Sabela Fernández-Aguado³⁶, Natalia Boix- Martí³⁷, Eric Kirkegaard-Biosca³⁸, Iago Alvarez Saez³⁹, Ares Selles-Rius⁴⁰, Maribel Pérez⁴¹, Juan Cañete⁴², Sara Marsal¹ and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁵Hospital Universitario de A Coruña, A Coruña, Spain, ⁶Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹³Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁴Hospital Ramon y Cajal, Madrid, Spain, ¹⁵Hospital León, LEON, Castilla y Leon, Spain, ¹⁶Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁷Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹⁸Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ²⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²¹Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ²²Hospital Universitario Central de Asturias, Oviedo, Spain, ²³Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁶Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁷Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²⁸Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ²⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ³⁴Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁵Hospital Gregorio Marañon, Madrid, Spain, ³⁶Hospital Universitario de Pontevedra, Pontevedra, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³⁹Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁴⁰Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Barcelona, Spain, ⁴²Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…
Abstract Number: 1672 • ACR Convergence 2025
Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood
Coziana Ciurtin¹, Ruby Gotch², Hannah Peckham¹, Robert Wilson², Muthana AlObaidi³ and Elizabeth C Jury¹, ¹University College London, London, United Kingdom, ²University College London Hospital NHS Trust, London, United Kingdom, ³Great Ormond Street Hospital, London, United Kingdom
Background/Purpose: Childhood Sjögren Disease (cSjD) is a rare clinical phenotype lacking research on long-term outcomes and impact on the quality of life of young people…
Abstract Number: 1390 • ACR Convergence 2025
Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
KARLA CHACON¹, ALBERTO ALEJANDRO MARQUEZ-SANCHEZ¹, Jorge Rojas-Serrano² and MAYRA MEJÍA¹, ¹Instituto Nacional de Enfermedades Respiratorias, CIUDAD DE MEXICO, Distrito Federal, Mexico, ²Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
Background/Purpose: Lymphocytic interstitial pneumonia (LIP) is a rare interstitial lung disease, most commonly associated with Sjögren’s syndrome, but it may also occur in the context…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 0510 • ACR Convergence 2025
A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease
Anna-Maria Hoffmann-Vold¹, Kastriot Kastrati², Marco Sprecher³, Emily Violette Langballe¹, Phuong Diep¹, Havard Fretheim¹, Helena Andersson¹, Paul Studenic⁴, Bojana Müller-Durovic³, Cathrine Brunborg¹, Cosimo Bruni⁵, Christian Clarenbach³, Thomas Frauenfelder⁶, Trond Mogens Aaløkken¹, Natasha Moe¹, Helmut Prosch⁴, Helga Radner², Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Univeristy Hospital Zurich, Zurich, Switzerland, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁷Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of Sjögren disease (SjD) patients, leading to increased morbidity and reduced survival. The true prevalence may be higher…
Abstract Number: 2396 • ACR Convergence 2025
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Gerber Gomez¹, Yipeng Cheng², Kristiana Nita², Michael Hausmann³, Christian Fischer¹ and Yasemin Ataman-Önal³, ¹Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ²AliveDx, Edinburgh, United Kingdom, ³AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…
Abstract Number: 2233 • ACR Convergence 2025
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Caleb Marlin¹, Roopa Madhu², Erin Theisen³, Liz Bradshaw⁴, Ce Gao⁵, Thomas Eisenhaure⁶, Nicolas Sugiarto⁷, Accelerating Medicines Partnertship: Autoimmune and Immune Mediated Diseases⁸, Jill Buyon⁹, Michelle Petri¹⁰, Brad Rovin¹¹, Victoria Werth¹², Ellen M. Gravallese¹³, Jennifer Anolik¹⁴, Larry Moreland¹⁵, Laura Donlin¹⁶, Christopher Ritchlin¹⁷, Jose Scher¹⁸, Johann Gudjonsson¹⁹, Wilson Liao²⁰, Alexis Ogdie²¹, Caroline Shiboski²², A. Darise Farris¹, Alan Baer²³, Blake M. Warner²⁴, Jose Clemente²⁵, Adriana Heguy²⁶, Michael Brenner²⁷, Nir Hacohen²⁸, Joel Guthridge¹, Judith James¹, Soumya Raychaudhuri²⁹, Lam Tsoi¹⁹, Xiang Zhou³⁰, Joshua Welch³⁰, Rachael Clark³, ilya Korsunsky²⁹, Christopher Lessard¹ and Kevin Wei³¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Boston, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute, Boston, ⁸Multiple Institutions, Oklahoma City, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹The Ohio State University, Columbus, OH, ¹²University of Pennsylvania, Wynnewood, PA, ¹³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵University of Colorado, Denver, CO, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University of Rochester Medical Center, Canandaigua, NY, ¹⁸New York University School of Medicine, New York, NY, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰UCSF, San Francisco, CA, ²¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²²University of California San Francisco, San Francisco, CA, ²³Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Icahn School of Medicine at Mount Sinai, New York, NY, ²⁶NYU Grossman School of Medicine, New York, ²⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁸Broad Institute of MIT Harvard, Cambridge, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰University of Michigan, Ann Arbor, ³¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Autoimmune diseases affect more than 23.5 million Americans involving nearly every organ system of the human body. To identify shared, unique, and novel pathways…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].